Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

Treatment with biologic DMARDs vs standard therapy improved clinical response rates and flare outcomes among patients with polyarticular JIA.

Advances in biotechnology, a greater understanding of the immunopathogenesis of rheumatoid arthritis (RA) and a desire for more effective therapeutics have led to the development of a class of ...

SaveHealth reports on psoriatic arthritis medications, detailing options like DMARDs, biologics, and NSAIDs, including their ...

Rheumatoid arthritis (RA) disease activity and inflammatory markers are associated with major adverse cardiovascular events (MACEs) in biologic disease-modifying antirheumatic drug (bDMARD) nonusers ...

In recent years, the treatment of rheumatic inflammatory diseases has been revolutionized. With the advent of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), minimal ...

Biologic vs conventional DMARDs may offer cardioprotective benefits among patients with PsA, though an increased risk for infection requires vigilance.